title: Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients.
abstract: OBJECTIVE
  This study aims to investigate how immunosuppression influences the protein expression of antiapoptotic members of the Bcl-2 family-namely, Bcl-xL and Mcl-1-in nonmelanoma skin cancer (NMSC) and the peritumoral epidermis of renal transplant recipients.
  
  
  METHODS
  NMSC and peritumoral epidermis protein expression of Bcl-xL and Mcl-1 were assessed by immunohistochemistry in renal transplant recipients receiving tacrolimus or sirolimus and the general population not receiving immunosuppression.
  
  
  RESULTS
  NMSC from renal transplant recipients compared with patients not receiving immunosuppressant medications had a reduced Bcl-xL expression intensity (P = .042). Mcl-1 expression intensity in NMSC was decreased in tacrolimus-treated patients compared with sirolimus-treated patients and the nonimmunosuppressed population (P = .024). Bcl-xL expression intensity was increased in peritumoral epidermis compared with NMSC (P = .002).
  
  
  CONCLUSIONS
  It was shown for the first time that Bcl-xL and Mcl-1 expression are widespread in the peritumoral epidermis and NMSC of renal transplant recipients. Importantly in NMSC, Bcl-xL expression was reduced with immunosuppression exposure, and Mcl-1 expression was reduced in tacrolimus-treated compared with sirolimus-treated patients.
authors.affiliation: From the Departments of Renal Medicine and Michael.burke@health.qld.gov.au.
authors.forename: Michael T
authors.initials: MT
authors.lastname: Burke
authors.affiliation: Centre for Kidney Disease Research, School of Medicine, University of Queensland, Translational Research Institute, Brisbane, Australia;
authors.forename: Christudas
authors.initials: C
authors.lastname: Morais
authors.affiliation: Pathology, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia;
authors.forename: Kimberley A
authors.initials: KA
authors.lastname: Oliver
authors.affiliation: IQ Pathology, Brisbane, Australia; The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia;
authors.forename: Duncan L J
authors.initials: DL
authors.lastname: Lambie
authors.affiliation: Centre for Kidney Disease Research, School of Medicine, University of Queensland, Translational Research Institute, Brisbane, Australia;
authors.forename: Glenda C
authors.initials: GC
authors.lastname: Gobe
authors.affiliation: Central Northern Adelaide Renal and Transplantation Services, Adelaide, Australia; Department of Medicine, The University of Adelaide, Adelaide, Australia;
authors.forename: Robert P
authors.initials: RP
authors.lastname: Carroll
authors.affiliation: School of Pharmacy, The University of Queensland, Brisbane, Australia;
authors.forename: Christine E
authors.initials: CE
authors.lastname: Staatz
authors.affiliation: Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia; and.
authors.forename: Sudipta
authors.initials: S
authors.lastname: Sinnya
authors.affiliation: Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia; and.
authors.forename: H Peter
authors.initials: HP
authors.lastname: Soyer
authors.affiliation: QIMR Berghofer Medical Research Institute, Brisbane, Australia.
authors.forename: Clay
authors.initials: C
authors.lastname: Winterford
authors.affiliation: The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia;
authors.forename: Nikolas K
authors.initials: NK
authors.lastname: Haass
authors.affiliation: From the Departments of Renal Medicine and.
authors.forename: Scott B
authors.initials: SB
authors.lastname: Campbell
authors.affiliation: From the Departments of Renal Medicine and.
authors.forename: Nicole M
authors.initials: NM
authors.lastname: Isbel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis; D002280:Basal Cell Carcinoma / Q000378:metabolism* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D008938:Mitosis; D064549:Myeloid Cell Leukemia Sequence 1 Protein / Q000378:metabolism*; D020123:Sirolimus / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000378:metabolism* / Q000473:pathology; D016559:Tacrolimus / Q000627:therapeutic use; D066027:Transplant Recipients; D051020:bcl-X Protein / Q000378:metabolism*
chemical_list: C494811:BCL2L1 protein, human; D007166:Immunosuppressive Agents; C579095:MCL1 protein, human; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D051020:bcl-X Protein; D020123:Sirolimus; D016559:Tacrolimus
keywords: Apoptosis; Bcl-xL; Immunohistochemistry; Mcl-1; Mitosis; Nonmelanoma skin cancer; Renal transplantation